Regulation of prostate cancer by hormone-responsive G protein-coupled receptors

Regulation of prostate cancer by androgen and androgen receptor (AR), and blockade of AR signaling by AR antagonists and steroidogenic enzyme inhibitors have been extensively studied. G protein-coupled receptors (GPCRs) are a family of membrane receptors that regulate almost all physiological proces...

Full description

Saved in:
Bibliographic Details
Published inPharmacology & therapeutics (Oxford) Vol. 191; pp. 135 - 147
Main Authors Wang, Wei, Chen, Zhao-Xia, Guo, Dong-Yu, Tao, Ya-Xiong
Format Journal Article
LanguageEnglish
Published England Elsevier Inc 01.11.2018
Subjects
Androgen receptor
Castration resistance
G protein-coupled receptors
Prostate cancer
Reproduction
G protein-coupled receptors
PLC
LDL-A
cAMP
CYP17A1
ADT
DHT
Reproduction
GHS
c-JNK
LHR
FSH
GnRH
PSA
GHSR
PKA
Castration resistance
PKC
DAG
MAPK
IP3
GnRHR
AR
ERK1/2
FSHR
RXFP
Androgen receptor
GPCR
BPH
LH
Prostate cancer
CRPC
HPG
Online AccessGet full text

Cover

More Information
Summary:Regulation of prostate cancer by androgen and androgen receptor (AR), and blockade of AR signaling by AR antagonists and steroidogenic enzyme inhibitors have been extensively studied. G protein-coupled receptors (GPCRs) are a family of membrane receptors that regulate almost all physiological processes. Nearly 40% of FDA-approved drugs in the market target GPCRs. A variety of GPCRs that mediate reproductive function have been demonstrated to be involved in the regulation of prostate cancer. These GPCRs include gonadotropin-releasing hormone receptor, luteinizing hormone receptor, follicle-stimulating hormone receptor, relaxin receptor, ghrelin receptor, and kisspeptin receptor. We highlight here GPCR regulation of prostate cancer by these GPCRs. Further therapeutic approaches targeting these GPCRs for the treatment of prostate cancer are summarized.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2018.06.005